Kenneth Blum

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/826722/publications.pdf

Version: 2024-02-01

243 papers	10,493 citations	34105 52 h-index	40979 93 g-index
247 all docs	247 docs citations	247 times ranked	5821 citing authors

#	Article	IF	Citations
1	The Reward Deficiency Syndrome: A Biogenetic Model for the Diagnosis and Treatment of Impulsive, Addictive and Compulsive Behaviors. Journal of Psychoactive Drugs, 2000, 32, 1-112.	1.7	794
2	Allelic Association of Human Dopamine D2 Receptor Gene in Alcoholism. JAMA - Journal of the American Medical Association, 1990, 263, 2055.	7.4	748
3	Reward deficiency syndrome: genetic aspects of behavioral disorders. Progress in Brain Research, 2000, 126, 325-341.	1.4	535
4	Weight Gain Is Associated with Reduced Striatal Response to Palatable Food. Journal of Neuroscience, 2010, 30, 13105-13109.	3.6	336
5	Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics and Genomics, 1995, 5, 121-141.	5.7	281
6	Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug and Alcohol Dependence, 1993, 33, 271-285.	3.2	244
7	Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol, 1991, 8, 409-416.	1.7	216
8	“Liking” and “Wanting” Linked to Reward Deficiency Syndrome (RDS): Hypothesizing Differential Responsivity in Brain Reward Circuitry. Current Pharmaceutical Design, 2012, 18, 113-118.	1.9	194
9	Are dopaminergic genes involved in a predisposition to pathological aggression?. Medical Hypotheses, 2005, 65, 703-707.	1.5	175
10	Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theoretical Biology and Medical Modelling, 2008, 5, 24.	2.1	163
11	Genetic Addiction Risk Score (GARS): Molecular Neurogenetic Evidence for Predisposition to Reward Deficiency Syndrome (RDS). Molecular Neurobiology, 2014, 50, 765-796.	4.0	157
12	Dopamine and glucose, obesity, and reward deficiency syndrome. Frontiers in Psychology, 2014, 5, 919.	2.1	155
13	Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatric Disease and Treatment, 2008, 4, 893.	2.2	140
14	Increased prevalence of the Taq I A1allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics and Genomics, 1996, 6, 297-305.	5.7	138
15	The Addictive Brain: All Roads Lead to Dopamine. Journal of Psychoactive Drugs, 2012, 44, 134-143.	1.7	138
16	rsfMRIeffects of KB220Zâ„¢ on neural pathways in reward circuitry of abstinent genotyped heroin addicts. Postgraduate Medicine, 2015, 127, 232-241.	2.0	135
17	Overcoming qEEG Abnormalities and Reward Gene Deficits during Protracted Abstinence in Male Psychostimulant and Polydrug Abusers Utilizing Putative Dopamine D₂Agonist Therapy: Part 2. Postgraduate Medicine, 2010, 122, 214-226.	2.0	119
18	Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)â„¢ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. Journal of Behavioral Addictions, 2014, 3, 149-156.	3.7	119

#	Article	IF	Citations
19	Molecular role of dopamine in anhedonia linked to reward deficiency syndrome RDS and anti- reward systems. Frontiers in Bioscience - Scholar, 2018, 10, 309-325.	2.1	111
20	Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects: Selecting Appropriate Phenotypes for Reward Dependence Behaviors. International Journal of Environmental Research and Public Health, 2011, 8, 4425-4459.	2.6	106
21	Reward Circuitry Dopaminergic Activation Regulates Food and Drug Craving Behavior. Current Pharmaceutical Design, 2011, 17, 1158-1167.	1.9	97
22	Enkephalinase inhibition: Regulation of ethanol intake in genetically predisposed mice. Alcohol, 1987, 4, 449-456.	1.7	93
23	Enhanced functional connectivity and volume between cognitive and reward centers of naÃ¯ve rodent brain produced by pro-dopaminergic agent KB220Z. PLoS ONE, 2017, 12, e0174774.	2.5	92
24	Genetic addiction risk score GARS trade a predictor of vulnerability to opioid dependence. Frontiers in Bioscience - Elite, 2018, 10, 175-196.	1.8	92
25	Dopamine homeostasis brain functional connectivity in reward deficiency syndrome. Frontiers in Bioscience - Landmark, 2017, 22, 669-691.	3.0	88
26	Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape. Current Neuropharmacology, 2017, 15, 184-194.	2.9	87
27	Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction. Journal of Reward Deficiency Syndrome, 2015, 01, 95-104.	1.0	83
28	Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: A preliminary report. Food and Function, 2012, 3, 40-48.	4.6	82
29	Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. Medical Hypotheses, 2009, 72, 14-22.	1.5	80
30	Systematic Evaluation of â€œComplianceâ€•to Prescribed Treatment Medications and â€œAbstinenceâ€•from Psychoactive Drug Abuse in Chemical Dependence Programs: Data from the Comprehensive Analysis of Reported Drugs. PLoS ONE, 2014, 9, e104275.	2.5	77
31	Genotrimâ„¢, a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamineâ€“glucose correlation demonstrating reward deficiency syndrome (RDS). Medical Hypotheses, 2007, 68, 844-852.	1.5	76
32	Long Term Suboxoneâ„¢ Emotional Reactivity As Measured by Automatic Detection in Speech. PLoS ONE, 2013, 8, e69043.	2.5	73
33	The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery. Journal of Reward Deficiency Syndrome, 2015, 01, 46-64.	1.0	72
34	Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note. Journal of Addiction Research & Therapy, 2013, 04, .	0.2	72
35	Neurogenetics of Dopaminergic Receptor Supersensitivity in Activation of Brain Reward Circuitry and Relapse: Proposing â€œDeprivation-Amplification Relapse Therapyâ€•(DART). Postgraduate Medicine, 2009, 121, 176-196.	2.0	70
36	Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. Biomedical Journal of Scientific & Technical Research, 2018, 2, 1-4.	0.1	70

#	Article	IF	Citations
37	Sex, Drugs, and Rock â€˜Nâ€™ Roll: Hypothesizing Common Mesolimbic Activation as a Function of Reward Gene Polymorphisms. Journal of Psychoactive Drugs, 2012, 44, 38-55.	1.7	68
38	Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: Double-blind placebo-controlled study of the nutritional adjunct SAAVEâ„¢. Alcohol, 1988, 5, 481-493.	1.7	66
39	Nutrigenomic targeting of carbohydrate craving behavior: Can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map?. Medical Hypotheses, 2009, 73, 427-434.	1.5	66
40	Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?. Molecular Neurobiology, 2015, 52, 1862-1869.	4.0	66
41	The Psychoactive Designer Drug and Bath Salt Constituent MDPV Causes Widespread Disruption of Brain Functional Connectivity. Neuropsychopharmacology, 2016, 41, 2352-2365.	5.4	66
42	A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone. Substance Use and Misuse, 2018, 53, 220-229.	1.4	66
43	Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms. Journal of Addiction Research & Therapy, 2013, 03, 139.	0.2	65
44	Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With â€œDopamine Homeostasisâ€•in Reward Deficiency Syndrome (RDS). Substance Use and Misuse, 2017, 52, 535-547.	1.4	62
45	Low Dopamine Function in Attention Deficit/Hyperactivity Disorder: Should Genotyping Signify Early Diagnosis in Children?. Postgraduate Medicine, 2014, 126, 153-177.	2.0	61
46	Opioid Substitution Therapy: Achieving Harm Reduction While Searching for a Prophylactic Solution. Current Pharmaceutical Biotechnology, 2019, 20, 180-182.	1.6	59
47	Putative Role of Isoquinoline Alkaloids in Alcoholism: A Link to Opiates. Alcoholism: Clinical and Experimental Research, 1978, 2, 113-120.	2.4	57
48	BARHL1 Is Downregulated in Alzheimerâ€™s Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways. Genes, 2017, 8, 245.	2.4	57
49	The Genetics of Problem and Pathological Gambling: A Systematic Review. Current Pharmaceutical Design, 2014, 20, 3993-3999.	1.9	57
50	Ethanol intoxication as function of genotype dependent responses in three inbred mice strains. Pharmacology Biochemistry and Behavior, 1982, 16, 13-15.	2.9	56
51	Co-occurrences of substance use and other potentially addictive behaviors: Epidemiological results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study. Journal of Behavioral Addictions, 2020, 9, 272-288.	3.7	56
52	Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term. , 2016, 2, 14-21.		56
53	Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD). Global Journal of Addiction & Rehabilitation Medicine, 2017, 1, .	0.1	56
54	Identification of an Isoquinoline Alkaloid after Chronic Exposure to Ethanol. Alcoholism: Clinical and Experimental Research, 1978, 2, 133-137.	2.4	53

#	Article	IF	Citations
55	Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors. Frontiers in Psychiatry, 2018, 9, 548.	2.6	53
56	Conceptualizing Addiction From an Osteopathic Perspective: Dopamine Homeostasis. Journal of Osteopathic Medicine, 2018, 118, 115-118.	0.8	52
57	Epigenetics in Developmental Disorder: ADHD and Endophenotypes. Journal of Genetic Syndromes & Gene Therapy, 2011, 2, .	0.2	52
58	Neurodynamics of Relapse Prevention: A Neuronutrient Approach to Outpatient DUI Offenders. Journal of Psychoactive Drugs, 1990, 22, 173-187.	1.7	51
59	Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: A hypothesis. Medical Hypotheses, 2007, 69, 1054-1060.	1.5	51
60	Prolonged P300 latency in a neuropsychiatric population with the D2 Dopamine receptor A1 allele. Pharmacogenetics and Genomics, 1994, 4, 313-322.	5.7	49
61	Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. Medical Hypotheses, 2004, 63, 538-548.	1.5	49
62	Neurogenetic and Epigenetic Correlates of Adolescent Predisposition to and Risk for Addictive Behaviors as a Function of Prefrontal Cortex Dysregulation. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 286-292.	1.3	49
63	Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability. Current Neuropharmacology, 2010, 8, 335-358.	2.9	49
64	LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome. Advances in Therapy, 2008, 25, 894-913.	2.9	47
65	Acute Intravenous Synaptamine Complex Variant KB220â„¢ â€œNormalizesâ€•Neurological Dysregulation in Patients during Protracted Abstinence from Alcohol and Opiates as Observed Using Quantitative Electroencephalographic and Genetic Analysis for Reward Polymorphisms: Part 1, Pilot Study with 2 Case Reports. Postgraduate Medicine, 2010, 122, 188-213.	2.0	47
66	Neurogenetics and Clinical Evidence for the Putative Activation of the Brain Reward Circuitry by a Neuroadaptagen: Proposing an Addiction Candidate Gene Panel Map. Journal of Psychoactive Drugs, 2011, 43, 108-127.	1.7	47
67	The effects of residential dual diagnosis treatment on alcohol abuse. Journal of Systems and Integrative Neuroscience, 2017, 3, .	0.6	47
68	P300 (Latency) Event-Related Potential: An Accurate Predictor of Memory Impairment. Clinical EEG (electroencephalography), 2003, 34, 124-139.	0.9	45
69	Reward deficiency syndrome in obesity: A preliminary cross-sectional trial with a genotrim variant. Advances in Therapy, 2006, 23, 1040-1051.	2.9	45
70	Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and Leptin genes and up-regulation of the adiponectin gene. Lipids in Health and Disease, 2008, 7, 44.	3.0	44
71	Enhancement of Alcohol Withdrawal Convulsions in Mice by Haloperidol. Clinical Toxicology, 1976, 9, 427-434.	0.5	43
72	Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis. , 2020, , 297-306.		43

#	Article	IF	Citations
73	Neuro-Genetics of Reward Deficiency Syndrome (Rds) as the Root Cause of â€œAddiction Transferâ€• A New Phenomena Common after Bariatric Surgery. Journal of Genetic Syndromes & Gene Therapy, 2013, 04, .	0.2	42
74	Hypodopaminergia and â€œPrecision Behavioral Managementâ€•(PBM): It is a Generational Family Affair. Current Pharmaceutical Biotechnology, 2020, 21, 528-541.	1.6	42
75	Opiate-like activity of salsolinol on the electrically stimulated guinea pig ileum. Life Sciences, 1979, 25, 2205-2210.	4.3	41
76	Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS). Medical Hypotheses, 2010, 74, 513-520.	1.5	41
77	The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis. Current Pharmaceutical Design, 2018, 23, 6050-6061.	1.9	40
78	Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: A hypothesis. Medical Hypotheses, 2011, 76, 576-584.	1.5	39
79	Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: Role of enhanced brain reward functional connectivity and homeostasis redeeming joy. Journal of Behavioral Addictions, 2015, 4, 106-115.	3.7	39
80	NIDA-Drug Addiction Treatment Outcome Study (DATOS) Relapse as a Function of Spirituality/Religiosity. Journal of Reward Deficiency Syndrome, 2015, 01, 36-45.	1.0	35
81	Improvement of Inpatient Treatment of the Alcoholic as a Function of Neurotransmitter Restoration: A Pilot Study. Substance Use and Misuse, 1988, 23, 991-998.	0.6	33
82	Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?. Journal of the Neurological Sciences, 2020, 418, 117137.	0.6	32
83	Using the Neuroadaptagen KB200zâ„¢ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis. Journal of Reward Deficiency Syndrome, 2015, 01, 24-35.	1.0	31
84	Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward Circuitry. Journal of Genetic Syndromes & Gene Therapy, 2012, 03, 1000115.	0.2	31
85	KB220Zâ„¢ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?. , 2016, 2, 3-13.		29
86	Dopamine D2 gene expression interacts with environmental enrichment to impact lifespan and behavior. Oncotarget, 2016, 7, 19111-19123.	1.8	29
87	Enhancement of Attention Processing by Kantrollâ„¢ in Healthy Humans: A Pilot Study. Clinical EEG (electroencephalography), 1997, 28, 68-75.	0.9	28
88	Neuropsychopharmacology and Neurogenetic Aspects of Executive Functioning: Should Reward Gene Polymorphisms Constitute a Diagnostic Tool to Identify Individuals at Risk for Impaired Judgment?. Molecular Neurobiology, 2012, 45, 298-313.	4.0	28
89	Gene Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome. Advances in Therapy, 2007, 24, 402-414.	2.9	27
90	Can the Chronic Administration of the Combination of Buprenorphine and Naloxone Block Dopaminergic Activity Causing Anti-reward and Relapse Potential?. Molecular Neurobiology, 2011, 44, 250-268.	4.0	27

#	Article	IF	Citations
91	Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS). Journal of the Neurological Sciences, 2020, 411, 116733.	0.6	27
92	Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence. Journal of Addiction Research & Therapy, 2013, 04, 1000163.	0.2	26
93	Pre-clinical models of reward deficiency syndrome: A behavioral octopus. Neuroscience and Biobehavioral Reviews, 2020, 115, 164-188.	6.1	26
94	Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine. Current Neuropharmacology, 2020, 18, 578-595.	2.9	26
95	Improvement of Cocaine-Induced Neuromodulator Deficits by the Neuronutrient Tropamineâ„¢. Journal of Psychoactive Drugs, 1988, 20, 315-331.	1.7	24
96	Managing Terrorism or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: A Comprehensive Review. International Journal of Environmental Research and Public Health, 2014, 11, 4158-4200.	2.6	23
97	Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land?. Expert Opinion on Biological Therapy, 2015, 15, 973-985.	3.1	23
98	A Shared Molecular and Genetic Basis for Food and Drug Addiction. Psychiatric Clinics of North America, 2015, 38, 419-462.	1.3	23
99	Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization. Molecular Neurobiology, 2019, 56, 7836-7850.	4.0	23
100	Administration of a putative pro-dopamine regulator, a neuronutrient, mitigates alcohol intake in alcohol-preferring rats. Behavioural Brain Research, 2020, 385, 112563.	2.2	23
101	The therapeutic potential of exercise for neuropsychiatric diseases: A review. Journal of the Neurological Sciences, 2020, 412, 116763.	0.6	23
102	Enhancement of ethanol-induced withdrawal convulsions by blockade of 5-hydroxytryptamine receptors. Journal of Pharmacy and Pharmacology, 2011, 28, 832-835.	2.4	22
103	A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer. BMC Genomics, 2013, 14, S5.	2.8	22
104	Hypothesizing Music Intervention Enhances Brain Functional Connectivity Involving Dopaminergic Recruitment: Common Neuro-correlates to Abusable Drugs. Molecular Neurobiology, 2017, 54, 3753-3758.	4.0	22
105	Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch. Journal of the Neurological Sciences, 2021, 420, 117252.	0.6	22
106	Delayed P300 latency correlates with abnormal Test of Variables of Attention (TOVA) in adults and predicts early cognitive decline in a clinical setting. Advances in Therapy, 2006, 23, 582-600.	2.9	21
107	Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT)â„¢ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study. Journal of Psychoactive Drugs, 2012, 44, 398-409.	1.7	21
108	Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)?. Journal of Addiction Research & Therapy, 2014, 05, .	0.2	21

#	Article	IF	Citations
109	Substance use disorder a bio-directional subset of reward deficiency syndrome. Frontiers in Bioscience - Landmark, 2017, 22, 1534-1548.	3.0	21
110	High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial. Molecular Neurobiology, 2021, 58, 3335-3346.	4.0	21
111	Neurogenetic interactions and aberrant behavioral co-morbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths. Theoretical Biology and Medical Modelling, 2005, 2, 50.	2.1	20
112	The H-WaveÂ® device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. Advances in Therapy, 2008, 25, 644-657.	2.9	20
113	Hypothesizing that designer drugs containing cathinones (â€œbath saltsâ€) have profound neuro-inflammatory effects and dangerous neurotoxic response following human consumption. Medical Hypotheses, 2013, 81, 450-455.	1.5	20
114	Hypothesizing repetitive paraphilia behavior of a medication refractive Tourette's syndrome patient having rapid clinical attenuation with KB220Z-nutrigenomic amino-acid therapy (NAAT). Journal of Behavioral Addictions, 2013, 2, 117-124.	3.7	20
115	The DRD2 Taq1A A1 Allele May Magnify the Risk of Alzheimerâ€™s in Aging African-Americans. Molecular Neurobiology, 2018, 55, 5526-5536.	4.0	20
116	Synaptamine (SG8839),TM An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS). Trends in Applied Sciences Research, 2007, 2, 132-138.	0.4	20
117	Substance Use Disorder Exacerbates Brain Electrophysiological Abnormalities in a Psychiatrically-Ill Population. Clinical EEG (electroencephalography), 1996, 27, 5-28.	0.9	19
118	The H-WaveÂ® Device Induces NO-dependent Augmented Microcirculation and Angiogenesis, Providing Both Analgesia and Tissue Healing in Sports Injuries. Physician and Sportsmedicine, 2008, 36, 103-114.	2.1	19
119	Diagnosis and Healing In Veterans Suspected of Suffering from Post- Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation. Journal of Genetic Syndromes & Gene Therapy, 2012, 03, 1000116.	0.2	19
120	In Search of Reward Deficiency Syndrome (RDS)-Free Controls: The â€œHoly Grailâ€•in Genetic Addiction Risk Testing. Current Psychopharmacology, 2020, 9, 7-21.	0.3	18
121	â€œColdâ€•X5 Hairlaserâ„¢ used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study. BMC Research Notes, 2014, 7, 103.	1.4	17
122	Our evolved unique pleasure circuit makes humans different from apes: Reconsideration of data derived from animal studies. Journal of Systems and Integrative Neuroscience, 2018, 4, .	0.6	17
123	Coupling Neurogenetics (GARSâ„¢) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms. Journal of Reward Deficiency Syndrome, 2015, 1, 75-80.	1.0	17
124	Hoehn and Yahr staging of Parkinson rsquo s disease in relation to neuropsychological measures. Frontiers in Bioscience - Landmark, 2018, 23, 1370-1379.	3.0	16
125	Putative COVID- 19 Induction of Reward Deficiency Syndrome (RDS) and Associated Behavioral Addictions with Potential Concomitant Dopamine Depletion: Is COVID-19 Social Distancing a Double Edged Sword?. Substance Use and Misuse, 2020, 55, 2438-2442.	1.4	16
126	Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis. Frontiers in Psychiatry, 2021, 12, 623403.	2.6	16

#	Article	IF	Citations
127	Death by Opioids: Are there non-addictive scientific solutions?. Journal of Systems and Integrative Neuroscience, 2019, 5, .	0.6	16
128	Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction. Journal of Reward Deficiency Syndrome, 2015, 01, 65-68.	1.0	16
129	Clinical evidence for effectiveness of Phencalâ„¢ in maintaining weight loss in an open-label, controlled, 2-year study. Current Therapeutic Research, 1997, 58, 745-763.	1.2	15
130	Repetitive H-WaveÂ® device stimulation and program induces significant increases in the range of motion of post operative rotator cuff reconstruction in a double-blinded randomized placebo controlled human study. BMC Musculoskeletal Disorders, 2009, 10, 132.	1.9	15
131	Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD. Journal of Behavioral Addictions, 2018, 7, 192-203.	3.7	15
132	A Novel Precision Approach to Overcome the â€œAddiction Pandemicâ€•by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. Journal of Personalized Medicine, 2021, 11, 212.	2.5	15
133	Neuropsychiatric Genetics of Happiness, Friendships, and Politics: Hypothesizing Homophily (â€œBirds of) Tj ETQq1 1 0.784314 rgBT /O Syndromes & Gene Therapy, 2012, 03, .	0.2	15
134	Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It â€œBlowinâ€™ in the Windâ€?. Journal of Personalized Medicine, 2022, 12, 321.	2.5	15
135	Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior. Medical Hypotheses, 2014, 82, 606-614.	1.5	14
136	Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics. Cureus, 2015, 7, e348.	0.5	14
137	â€œDopamine homeostasisâ€•requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat Americaâ€™s drug epidemic. Journal of Systems and Integrative Neuroscience, 2017, 3, .	0.6	14
138	Addiction Treatment in America: After Money or Aftercare?. Journal of Reward Deficiency Syndrome, 2015, 01, 87-94.	1.0	14
139	Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29). Journal of Psychopharmacology, 2022, 36, 409-422.	4.0	14
140	The H-WaveÂ® small muscle fiber stimulator, a nonpharmacologic alternative for the treatment of chronic soft-tissue injury and neuropathic pain: an extended population observational study. Advances in Therapy, 2006, 23, 739-749.	2.9	13
141	Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?. Substance Use and Misuse, 2016, 51, 1674-1679.	1.4	13
142	Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) during Adolescent Brain Development. Current Psychopharmacology, 2021, 10, 181-196.	0.3	13
143	Morphine Withdrawal Reactions in Male and Female Mice. American Journal of Drug and Alcohol Abuse, 1976, 3, 363-368.	2.1	12
144	H-waveÂ®, a nonpharmacologic alternative for the treatment of patients with chronic soft tissue inflammation and neuropathic pain: A preliminary statistical outcome study. Advances in Therapy, 2006, 23, 446-455.	2.9	12

#	Article	IF	Citations
145	Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia. BMC Endocrine Disorders, 2009, 9, 21.	2.2	12
146	miRegulome: a knowledge-base of miRNA regulomics and analysis. Scientific Reports, 2015, 5, 12832.	3.3	12
147	Pilot clinical observations between food and drug seeking derived from fifty cases attending an eating disorder clinic. Journal of Behavioral Addictions, 2016, 5, 533-541.	3.7	12
148	Neurogenetics of acute and chronic opiate opioid abstinence treating symptoms and the cause. Frontiers in Bioscience - Landmark, 2017, 22, 1247-1288.	3.0	12
149	Reward Deficiency Syndrome: Attentional/Arousal Subtypes, Limitations of Current Diagnostic Nosology, and Future Research. Journal of Reward Deficiency Syndrome, 2015, 01, 6-9.	1.0	12
150	Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS). , 2017, 03, .		12
151	Hypothesizing that a Pro-Dopaminergic Regulator (KB220zâ„¢ Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence. Clinical Medical Reviews and Case Reports, 2016, 3, .	0.1	12
152	Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions. International Journal of Environmental Research and Public Health, 2021, 18, 11529.	2.6	12
153	Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia. Neuropsychiatric Disease and Treatment, 2010, 6, 681.	2.2	11
154	Evoked Potentials and Neuropsychological Tests Validate Positron Emission Topography (PET) Brain Metabolism in Cognitively Impaired Patients. PLoS ONE, 2013, 8, e55398.	2.5	11
155	Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality. Clinical Medical Reviews and Case Reports, 2015, 2, .	0.1	11
156	Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. Current Pharmaceutical Design, 2016, 22, 5837-5854.	1.9	11
157	Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case. Open Journal of Clinical & Medical Case Reports, 2016, 2, .	1.0	11
158	GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM): LESSONS LEARNED FROM AMERICA. Precision Medicine, 2017, 2, 17-22.	3.5	11
159	Innate properties of H-WaveÂ® device, a small fiber stimulator provides the basis for a paradigm shift of electro-therapeutic treatment of pain with increased functional restoration associated with human neuropathies by affecting tissue circulation: a hypothesis. Medical Hypotheses, 2005, 64, 1066-1067.	1.5	10
160	Hâ€WaveÂ® induces arteriolar vasodilation in rat striated muscle via nitric oxideâ€mediated mechanisms. Journal of Orthopaedic Research, 2009, 27, 1248-1251.	2.3	10
161	Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro- Adaptive Therapy 12â„¢ [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic during Protracted Abstinence: Putative Anti-Craving Implications. Journal of Addiction Research & Therapy, 2013, 05, 1-7.	0.2	10
162	Drug Abuse Relapse Rates Linked to Level of Education: Can We Repair Hypodopaminergic-Induced Cognitive Decline With Nutrient Therapy?. Physician and Sportsmedicine, 2014, 42, 130-145.	2.1	10

#	Article	IF	Citations
163	The benefits of genetic addiction risk score (GARSÂ®) and pro-dopamine regulation in combating suicide in the American Indian population. Journal of Systems and Integrative Neuroscience, 2018, 4, .	0.6	10
164	Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual. Journal of Systems and Integrative Neuroscience, 2020, 6, .	0.6	10
165	Pharmacological Inhibition of Brain Fatty Acid Binding Protein Reduces Ethanol Consumption in Mice. , 2017, 03, .		10
166	Genetic Addiction Risk Score (GARS) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis. , 2018, 1, .		10
167	THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS. Precision Medicine, 2016, 1, 18-33.	3.5	10
168	FOXN3 and GDNF Polymorphisms as Common Genetic Factors of Substance Use and Addictive Behaviors. Journal of Personalized Medicine, 2022, 12, 690.	2.5	10
169	DNA based customized nutraceutical â€œgene therapyâ€•utilizing a genoscore: A hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human. Medical Hypotheses, 2006, 66, 1008-1018.	1.5	9
170	Hypothesizing that Marijuana Smokers are at a Significantly Lower Risk of Carcinogenicity Relative to Tobacco-Non-Marijuana Smokers: Evidenced Based on Statistical Reevaluation of Current Literature. Journal of Psychoactive Drugs, 2008, 40, 263-272.	1.7	9
171	Preliminary investigation of plasma levels of sex hormones and human growth factor(s), and P300 latency as correlates to cognitive decline as a function of gender. BMC Research Notes, 2009, 2, 126.	1.4	9
172	Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but Should Not Be Considered as an Anti-addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti- Reward. Journal of Reward Deficiency Syndrome, 2015, 01, 20-23.	1.0	9
173	The Benefits of Genetic Addiction Risk Score (GARSâ„¢) Testing in Substance Use Disorder (SUD). International Journal of Genomics and Data Mining, 2018, 03, .	0.1	9
174	Declinol, a Complex Containing Kudzu, Bitter Herbs (Gentian, Tangerine Peel)and Bupleurum, Significantly Reduced Alcohol Use Disorders Identification Test (AUDIT) Scores in Moderate to Heavy Drinkers: A Pilot Study. Journal of Addiction Research & Therapy, 2013, 04, .	0.2	9
175	Hypothesizing Darkness Induced Alcohol Intake Linked to Dopaminergic Regulation of Brain Function. Psychology, 2014, 05, 282-288.	0.5	9
176	Dopaminergic Neurogenetics of Sleep Disorders in Reward Deficiency Syndrome (RDS). , 2014, 03, 126.		8
177	Evoked Potentials and Memory/Cognition Tests Validate Brain Atrophy as Measured by 3T MRI (NeuroQuant) in Cognitively Impaired Patients. PLoS ONE, 2015, 10, e0133609.	2.5	8
178	Lyme and dopaminergic function: Hypothesizing reduced reward deficiency symptomatology by regulating dopamine transmission. Journal of Systems and Integrative Neuroscience, 2017, 3, .	0.6	8
179	Acupuncture as a Common Mode of Treatment for Drug Dependence: Possible Neurochemical Mechanisms. Journal of Psychedelic Drugs, 1978, 10, 105-115.	0.3	7
180	Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: Evidence supported by structural equation modeling (SEM) parameter estimates. Age, 2007, 29, 55-67.	3.0	7

#	Article	IF	Citations
181	Neurophysiological Measures and Alcohol Use Disorder (AUD): Hypothesizing Links between Clinical Severity Index and Molecular Neurobiological Patterns. Journal of Addiction Research & Therapy, 2014, 05, .	0.2	7
182	Can Genetic Testing Coupled with Enhanced Dopaminergic Activation Reduce Recidivism Rates in the Workers Compensation Legacy Cases?. Journal of Alcoholism and Drug Dependence, 2014, 02, .	0.2	7
183	In Vivo Formation of Isoquinoline Alkaloids: Effect of Time and Route of Administration of Ethanol. Advances in Experimental Medicine and Biology, 1980, 126, 73-86.	1.6	7
184	Menopause Analytical Hormonal Correlate Outcome Study (MAHCOS) and the Association to Brain Electrophysiology (P300) in a Clinical Setting. PLoS ONE, 2014, 9, e105048.	2.5	7
185	Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. Journal of Addiction Science, 2020, 06, .	0.5	7
186	Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake. Clinical Medical Reviews and Case Reports, 2016, 3, .	0.1	7
187	Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS). , 2017, 3, 3-13.		7
188	The Benefits of Genetic Addiction Risk Score (GARS) Testing in Substance Use Disorder (SUD). International Journal of Genomics and Data Mining, 2018, 2018, .	0.1	7
189	Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse. , 2018, 7, 564-579.		7
190	In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. Current Psychopharmacology, 2020, 9, 7-21.	0.3	7
191	Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors. International Journal of Environmental Research and Public Health, 2022, 19, 552.	2.6	7
192	A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing â€œPrecision Behavioral Managementâ€• Psychology Research and Behavior Management, 2021, Volume 14, 2115-2134.	2.8	7
193	Determination of Drugs in Biologic Specimens-A Review. Clinical Toxicology, 1974, 7, 477-495.	0.5	6
194	Nutrition Programs Enhance Exercise Effects on Body Composition and Resting Blood Pressure. Physician and Sportsmedicine, 2013, 41, 85-91.	2.1	6
195	Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility. Addiction Genetics, 2015, 2, 1-5.	0.5	6
196	Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone?. Journal of Systems and Integrative Neuroscience, 2017, 3, .	0.6	6
197	Chronic treatment and abstinence from methylphenidate exposure dose-dependently changes glucose metabolism in the rat brain. Brain Research, 2022, 1780, 147799.	2.2	6
198	The Reward Deficiency Syndrome and Links with Addictive and Related Behaviors. , 2022, , 1-16.		6

#	Article	IF	Citations
199	Brain Mapping the Effects of Chronic Aerobic Exercise in the Rat Brain Using FDG PET. Journal of Personalized Medicine, 2022, 12, 860.	2.5	6
200	Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?. International Journal of Environmental Research and Public Health, 2022, 19, 6395.	2.6	6
201	Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation. Journal of Personalized Medicine, 2022, 12, 1009.	2.5	6
202	Healing enhancement of chronic venous stasis ulcers utilizing H-WAVEÂ®device therapy: a case series. Cases Journal, 2010, 3, 54.	0.4	5
203	Molecular Neurobiology of Addiction Recovery. SpringerBriefs in Neuroscience, 2013, , .	0.1	5
204	Genospirituality: Our Beliefs, Our Genomes, and Addictions. Journal of Addiction Research & Therapy, 2013, 04, .	0.2	5
205	Epigenetic Repair of Terrifying Lucid Dreams by Enhanced Brain Reward Functional Connectivity and Induction of Dopaminergic Homeo - static Signaling. Current Psychopharmacology, 2021, 10, 170-180.	0.3	5
206	Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?. International Journal of Environmental Research and Public Health, 2021, 18, 9774.	2.6	5
207	Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics.. Cureus, 2015, 7, e290.	0.5	5
208	Hypothesizing High Negative Emotionality as a Function of Genetic Addiction Risk Severity (GARS) Testing in Alcohol Use Disorder (AUD). Journal of Systems and Integrative Neuroscience, 2020, 7, .	0.6	5
209	Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor Âµ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms?. Biomedicines, 2022, 10, 870.	3.2	5
210	Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) via Activation of Neuro-immunological Function in the Face of a Viral Pandemic. Current Psychopharmacology, 2021, 10, 86-97.	0.3	4
211	Hypothesizing Las Vegas and Sutherland Springs Mass Shooters Suffer from Reward Deficiency Syndrome: â€œBorn Badâ€• , 2017, 03, 28-31.		4
212	Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?. Clinical Medical Reviews and Case Reports, 2015, 2, .	0.1	4
213	Hypothesizing Molecular Genetics of the Holocaust: Were Dopaminergic Genes Involved or Brain Wash?. SOJ Psychology, 2016, 3, 1-5.	0.3	4
214	H-WaveÂ® effects on blood flow and angiogenesis in longitudinal studies in rats. Journal of Surgical Orthopaedic Advances, 2011, 20, 255-9.	0.1	4
215	Overcoming reward deficiency syndrome by the induction of â€œdopamine homeostasisâ€•instead of opioids for addiction: illusion or reality?. Journal of Osteopathic Medicine, 2022, .	0.8	4
216	Proposing a â€œBrain Health Checkup (BHC)â€•as a Global Potential â€œStandard of Careâ€•to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of â€œDopamine Homeostasisâ€• International Journal of Environmental Research and Public Health, 2022, 19, 5480.	2.6	4

#	Article	IF	Citations
217	Critical Analysis of White House Anti-Drug Plan. Global Journal of Addiction & Rehabilitation Medicine, 2017, 1, .	0.1	3
218	Physical Exercise Interventions for Drug Addictive Disorders. , 2017, 3, 17-20.		3
219	Pharmacological Inhibition of Brain Fatty Acid Binding Protein Reduces Ethanol Consumption in Mice. , 2017, 3, 21-27.		3
220	The long-term interaction of diet and dopamine D2 gene expression on brain microglial activation. Psychiatry Research - Neuroimaging, 2022, 320, 111430.	1.8	3
221	Holism: A Social Pharmacological Approach to Drug-Seeking Behavior. Journal of Psychoactive Drugs, 1981, 13, 369-371.	1.7	2
222	Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report. Journal of Medical Case Reports, 2010, 4, 305.	0.8	2
223	A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain. Journal of Genetic Syndromes & Gene Therapy, 2014, 05, 213.	0.2	2
224	Rapid Anti-Depressant Relief by Ketamine: Exploring A Complex Mechanism of Action. Current Psychopharmacology, 2019, 8, 99-112.	0.3	2
225	Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise. Current Psychopharmacology, 2021, 10, 123-137.	0.3	2
226	Polygenic and multi locus heritability of alcoholism: Novel therapeutic targets to overcome psychological deficits. Journal of Systems and Integrative Neuroscience, 2020, 7, .	0.6	2
227	Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. , 2020, 6, 1-4.		2
228	Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?. Acta Scientific Neurology, 2021, 4, 17-24.	0.1	2
229	Understanding that Addiction Is a Brain Disorder Offers Help and Hope. Health, 2022, 14, 684-695.	0.3	2
230	Addiction Research and Therapy in the 21st Century: Providing a Forum for Evidence -Based Addiction Medicine. Journal of Addiction Research & Therapy, 2013, 04, .	0.2	1
231	Precision Behavioral Management (PBM) A Novel Approach to Combat Post-Traumatic Stress Disorder (PTSD). SOJ Psychology, 2018, 5, .	0.3	1
232	Neurobiology and Spirituality in Addiction Recovery.. Acta Scientific Neurology, 2021, 4, 64-71.	0.1	1
233	Drugs: Have It Your Way or The Burger King Syndrome. Journal of Psychedelic Drugs, 1977, 9, 81-82.	0.3	0
234	Hypothesising that salts of iodine, strontium and caesium reverse ageing induced by nuclear radiation. International Journal of Low Radiation, 2013, 9, 38.	0.1	0

#	Article	IF	Citations
235	Hypothesizing Major Depression as a Subset of Reward Deficiency Syndrome (RDS) Linked to Polymorphic Reward Genes: Considerations for Translational Medicine Approaches for Future Drug Development. Handbook of Behavioral Neuroscience, 2019, , 419-426.	0.7	0
236	Meet Our Editor-in-Chief. Current Psychopharmacology, 2021, 10, 3-3.	0.3	0
237	Preliminary Hormonal Correlations in Female Patients as a Function of Somatic and Neurological Symptom Clusters: An Exploratory Development of a Multi-Hormonal Map for Bio-Identical Replacement Therapy (MHRT). Journal of Genetic Syndromes & Gene Therapy, 2013, 04, .	0.2	0
238	Buprenorphine and Naloxone Combinations and Dopamine. Current Psychopharmacology, 2018, 6, .	0.3	0
239	Transmodulation of Dopaminergic Signaling to Mitigate Hypodopminergia and Pharmaceutical Opioid-induced Hyperalgesia. Current Psychopharmacology, 2020, 9, 164-184.	0.3	0
240	Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220). , 2021, 13, 86-92.		0
241	Translational and Molecular Cytoarchitectural Genetic Guided Therapy to Induce Dopamine Homeostatic Neuro-signaling in Reward Deficiency and Associated Drug and Behavioral Addiction Seeking: A 60 Year Sojourn the Future is Now. , 2021, 10, 1-4.		0
242	Dopaminergic and other genes related to reward induced overeating, Bulimia, Anorexia Nervosa, and Binge eating. Expert Review of Precision Medicine and Drug Development, 0, , 1-17.	0.7	0
243	Neurogenetics of alcohol use disorder a subset of reward deficiency syndrome: candidate genes to be or not to be?. , 2022, , 105-160.		0